Novo Nordisk has entered a $1.46 billion agreement with Neomorph to develop molecular glue degraders targeting cardiometabolic disorders and rare diseases. The collaboration encompasses upfront and milestone payments for multiple targets.

Janux Therapeutics' stock value soared after early trial results suggested its immunotherapy technology could offer potent, safer treatments for solid tumors.

Viking Therapeutics' weight loss drug showed up to 15% body weight reduction in a 13-week mid-stage trial, surpassing similar drugs from Eli Lilly and Novo Nordisk. However, further validation is needed in Phase 3 trials.

The FDA is proposing to waive device registration fees for companies with annual revenues less than $1 million or those in bankruptcy. The move aims to alleviate financial burdens for smaller firms and those facing financial difficulties.

GSK's oral antibiotic, gepotidacin, has shown effectiveness in a late-stage gonorrhea trial, matching the current treatment regimen's success. It's also under consideration for urinary tract infections, with approvals sought later this year.

Zealand Pharma's stock soared after announcing positive Phase 2 trial results for survodutide, a liver disease treatment with potential in the obesity market.

Whilst Amsterdam has long been considered the global home of cannabis use, Western countries are slowly changing their stance on its use.

IQVIA has published a report "Global Trends in R&D 2024" exploring current developments and prospects in pharmaceutical research and development.

AstraZeneca's Tagrisso has received FDA approval for use with chemotherapy in treating advanced lung cancer with specific mutations.

AbbVie has announced Robert Michael, currently president and COO, will succeed Richard Gonzalez as CEO on July 1, moving into the role as executive chairman. The transition occurs as AbbVie faces significant market changes, notably biosimilar competition for its drug Humira.

Biotech firms are experiencing a fundraising boom in US equity markets, with a record $6.2 billion raised in January 2024 - the highest amount since February 2021.

Despite controversies and a failed study, Sarepta's Duchenne gene therapy, Elevidys, may soon expand its use beyond the initial age group.

Nanoform, the medicine performance-enhancing company, announced that it has won a grant of up to 4.3 million euros from Business Finland, the Finnish government organization for innovation funding and trade.

Lantern Pharma is advancing a new ADC program aimed at various solid tumor cancers. The program which uses a cryptophycin-based ADC has already shown very high potency in preclinical tests. 

Firefly Bio has launched with $94 million in Series A funding, introducing a novel platform utilizing degrader antibody conjugates (DACs) aimed at cancer treatment.

The U.S. FDA recently intensified its regulatory actions by issuing warning letters for manufacturing violations and the sale of counterfeit weight loss medications online. 

BioAge Labs has raised $170 million in Series D funding to enhance therapies for obesity and metabolic diseases. The round was led by Sofinnova Investments with participation from both new and existing investors. 

Bristol Myers Squibb (BMS) has partnered with deep tech company VantAI in a $674 million deal for its Generative AI-driven drug discovery platform.

Pfizer reportedly paid as much as $7 million for a 60-second commercial, leading to a finale which promoted its latest cancer initiative - LetsOutDoCancer.com.

The European Commission has approved CASGEVY™ (exagamglogene autotemcel) - the first CRISPR/Cas9 gene-edited therapy, for treating severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in patients aged 12 and older.